The firm’s experienced professionals help clients analyze financial alternatives, identify strategic and financial sources of capital, and structure and negotiate terms, which meet their objectives.

The protection is for patent application number 201880064280.9, which protects the CD19-expressing oncolytic virus, onCARlytics. Titled “Oncolytic Virus Expressing a CAR-T cell target and uses thereof ...

Alternative splicing (AS) of pre-mRNA plays a crucial role in tissue-specific gene regulation, with disease implications due to splicing defects. Predicting and manipulating AS can therefore uncover ...

The successful results of the studies of CD19-directed CAR T-cell therapy in acute lymphoblastic leukaemia and diffuse large B-cell lymphoma have resulted in the first approvals by the US Food and ...

IT之家3 月 13 日消息，晶泰科技昨晚宣布，该公司与瑞士洛桑联邦理工学院（EPFL）唐力教授团队联合创立的莱芒生物的代谢增强型 CD19 CAR-T 细胞治疗产品（Meta10-19 注射液）在研究者发起的临床试验（IIT）中，于浙江大学医学院附属第一医院成功完成了首例系统性 ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

According to Stoffels, the reboot will result in a "new fit-for-purpose organisational structure and operating ... dermatomyositis later this year, and CD19-targeted CAR-T therapies in mid-stage ...

After hours: March 19 at 4:02:30 PM EDT Loading Chart for KYTX ...

SG299 is a CD8-targeted fusosome that delivers to CD8+ T cells the genetic material to make CD19-directed CAR T cells while avoiding delivery to potentially ... and has developed programs to transform ...